Tenaya Therapeutics
TNYA
90 hedge funds and large institutions have $293M invested in Tenaya Therapeutics in 2024 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 27 increasing their positions, 26 reducing their positions, and 7 closing their positions.
4,767% more call options, than puts
Call options by funds: $292K | Put options by funds: $6K
243% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 7
93% more capital invested
Capital invested by funds: $151M → $293M (+$142M)
22% more funds holding
Funds holding: 74 → 90 (+16)
2.78% more ownership
Funds ownership: 68.57% → 71.35% (+2.8%)
4% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 26
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
+$13.7M |
| 2 |
IHAM
Integral Health Asset Management
New York
|
+$10.8M |
| 3 |
VA
VR Adviser
New York
|
+$7.44M |
| 4 |
BlackRock
New York
|
+$4.37M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$3.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.73M |
| 2 |
Renaissance Technologies
New York
|
-$2M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.18M |
| 4 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$713K |
| 5 |
Millennium Management
New York
|
-$610K |
TNYA Hedge Fund Activity: Q1 2024 in Review
90 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Tenaya Therapeutics (TNYA) for Q1 2024, worth a combined $293M — up 93% from $151M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new TNYA positions and 7 closed out — a net gain of 17 holders — while 27 added to existing stakes and 26 trimmed.
The largest buyer was Octagon Capital Advisors, opening a new position worth an estimated $13.7M. The largest seller was T. Rowe Price Associates, cutting an estimated $5.73M.
- 90 institutional investors held Tenaya Therapeutics (TNYA) as of Q1 2024, up from 74 in Q4 2023.
- Funds reported $293M of Tenaya Therapeutics stock for Q1 2024, up 93% quarter-over-quarter.
- 24 funds opened new Tenaya Therapeutics positions in Q1 2024 and 7 closed out, a net change of +17 holders.
- The largest Tenaya Therapeutics buyer in Q1 2024 was Octagon Capital Advisors, an estimated $13.7M added.
- The largest Tenaya Therapeutics seller in Q1 2024 was T. Rowe Price Associates, an estimated $5.73M sold.
Based on aggregated 13F filings for Q1 2024.